Cited by 277Cancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Open access

Conforti, Fabio, Pala, Laura, Bagnardi, Vincenzo, Viale, Giuseppe, De Pas, Tommaso, Pagan, Eleonora, Pennacchioli, Elisabetta, Cocorocchio, Emilia, Ferrucci, Pier Francesco, De Marinis, Filippo, Gelber, Richard D, Goldhirsch, Aron·2019·JNCI: Journal of the National Cancer Institute

DOI 10.1093/jnci/djz094PMC PMC6695312

Open this paper in CoChat — free account Open PDF

Abstract

Background: We previously showed that therapy with anti–checkpoints T-lymphocyte-associated protein 4 (anti–CTLA-4) or antiprogrammed cell death protein 1 (anti–PD-1) agents was more effective for men as compared with women. However, because the sex-dimorphism of the immune system is complex, involving multiple elements of immune responses, it is possible that women could derive larger benefit than men from strategies other than therapy with immune checkpoint inhibitors (ICIs) alone. Here we investigated whether women could derive larger benefit than men from the combination of chemotherapy and anti-PD-1 or anti-PD-L1. Methods: We performed two meta-analyses. The first included all randomized controlled trials (RCTs) testing anti-PD1 and anti–PD-L1 plus chemotherapy vs chemotherapy to assess different efficacy between men and women. The second included all RCTs of first-line systemic treatment in advanced non-small cell lung cancer testing anti–PD-1/PD-L1 given either alone or combined with chemotherapy to assess the different efficacy of these two immunotherapeutic strategies according to patients’ sex. For each RCT included in the two meta-analyses, first, a trial-specific ratio of hazard ratios (HRs) was calculated from the ratio of the reported hazard ratios in men and in women; second, these trial-specific ratios of hazard ratios were combined across trials using a random-effects model to obtain a pooled hazard ratios ratio. A pooled HRs ratio estimate lower than 1 indicates a greater treatment effect in men, and higher than 1 a greater effect in women. Results: Eight RCTs were included in the first meta-analysis. The pooled overall survival hazard ratios (OS-HRs) comparing anti–PD-1/PD-L1 plus chemotherapy vs chemotherapy was 0.76 (95% confidence interval [CI] = 0.66 to 0.87) for men and 0.48 (95% CI = 0.35 to 0.67) for women. The pooled ratio of the overall survival hazard ratios reported in men vs women was 1.56 (95% CI = 1.21 to 2.01), indicating a statistically significant greater effect for women. Six RCTs were included in the second meta-analysis: three tested an anti-PD-1 alone, whereas three RCTs tested anti-PD-1/PD-L1 plus chemotherapy. The pooled overall survival hazard ratios were 0.78 (95% CI = 0.60 to 1.00) in men and 0.97 (95% CI = 0.79 to 1.19) in women for anti–PD-1 alone, compared with 0.76 (95% CI = 0.64 to 0.91) in men and 0.44 (95% CI = 0.25 to 0.76) in women for anti–PD-1/PD-L1 plus chemotherapy. The pooled ratio of overall survival hazard ratios was 0.83 (95% CI = 0.65 to 1.06) for anti–PD-1 alone, indicating a greater effect in men, and 1.70 (95% CI = 1.16 to 2.49) for anti–PD-1/PD-L1 plus chemotherapy, indicating a greater effect in women. Conclusion: Women with advanced lung cancer derived a statistically significantly larger benefit from the addition of chemotherapy to anti–PD-1/PD-L1 as compared with men.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/jnci/djz094

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350

Show all 34 references

Sorted by citations

Items 101–200 of 277

Intratumoral heterogeneity and immunotherapy resistance: clinical implications
Keenan, B. P., Yadav, M., Ansstas, G., Fabrizio, D. A., Murugesan, K., Montesion, M., Niyogi, D. G., Mellman, I., & Melero, I. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.1239 · Cited by 19
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
Scott, S. C., Shao, X. M., Niknafs, N., Balan, A., Pereira, G., Marrone, K. A., Lam, V. K. L., Murray, J. C., Feliciano, J. L., Levy, B. P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.945798 · Cited by 15
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients
Pasello, G., Fabricio, A. S. C., Bianco, P. D., Salizzato, V., Favaretto, A. G., Piccin, L., Zustovich, F., Fabozzi, A., Rossi, C. D., Pigozzo, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04920-6 · Cited by 18
The 5-Ws of immunotherapy in head and neck cancer
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Rocco, C. D., Amirhassankhani, S., Sirgiovanni, G., Occhipinti, M. A., Napoli, V. M., Emiliani, A., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103041 · Cited by 15
Caloric Restriction Alleviates Radiation Injuries In A Sex-Dependent Fashion
Li, Y., Dong, J., Xiao, H., Wang, B., Chen, Z., Zhang, S., Jin, Y., Li, Y., Fan, S., & Cui, M. (2021) · The FASEB Journal · doi:10.1096/fj.202100351rr · Cited by 15
Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis
Tuminello, S., Alpert, N., Veluswamy, R. R., Kumar, A., Gomez, J. E., Flores, R. M., & Taioli, E. (2022) · BMC Cancer · doi:10.1186/s12885-022-09187-y · Cited by 15
Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Wang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., & He, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145128 · Cited by 15
Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis
Ding, Y., Lei, S., Wang, L., Tang, L., Zhang, Y., Liao, Y., Deng, X., Li, Y., Gong, Y., & Li, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107925 · Cited by 16
Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development
Katleba, K., Ghosh, P., & Mudryj, M. M. (2023) · Biomedicines · doi:10.3390/biomedicines11082215 · Cited by 14
Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
Rodríguez-Lara, V., Soca‐Chafre, G., Ávila-Costa, M. R., Whaley, J. J. J., Rodríguez‐Cid, J. R., Ordóñez-Librado, J. L., Rodrı́guez, E., & Heredia-Jara, N. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210297 · Cited by 16
Sex-specific outcomes in cancer therapy: the central role of hormones
Bakhshi, P., Ho, J. Q., & Zanganeh, S. (2024) · Frontiers in Medical Technology · doi:10.3389/fmedt.2024.1320690 · Cited by 14
Treating sex and gender differences as a continuous variable can improve precision cancer treatments
Yang, W., & Rubin, J. B. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00607-1 · Cited by 14
The estrogen pathway as a modulator of response to immunotherapy
Velez, M. A., Burns, T. F., & Stabile, L. P. (2019) · Immunotherapy · doi:10.2217/imt-2019-0024 · Cited by 13
Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
Callejo, A., Frigola, J., Iranzo, P., Carbonell, C., Mejia, N. M. D., Marmolejo, D. H., Assaf, J. D., Cedrés, S., Martínez‐Martí, A., Navarro, A., et al. (2021) · Cancers · doi:10.3390/cancers13133249 · Cited by 14
Downregulating testosterone levels enhance immunotherapy efficiency
Wang, L., Jiang, G., Jing, N., Liu, X., Zhuang, H., Zeng, W., Liang, W. P., & Liu, Z. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1981570 · Cited by 14
Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials
Takada, K., Shimokawa, M., Mizuki, F., Takamori, S., Takenaka, T., Miura, N., Shikada, Y., & Yoshizumi, T. (2022) · European journal of medical research · doi:10.1186/s40001-022-00789-7 · Cited by 15
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy—A Retrospective Bi-Centric Cohort Study
Lang, D., Brauner, A., Huemer, F., Rinnerthaler, G., Horner, A., Wass, R. E., Brehm, E., Kaiser, B., Greil, R., & Lamprecht, B. (2021) · Cancers · doi:10.3390/cancers14010093 · Cited by 13
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?
Venanzi, F. M., Bini, M., Nuccio, A., Toma, A. D., Lambertini, M., Ogliari, F. R., Oresti, S., Viganò, M. G., Brioschi, E., Polignano, M., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102648 · Cited by 13
Self-citation
Natural macromolecules polysaccharide-based drug delivery systems targeting tumor necrosis factor alpha receptor for the treatment of cancer: A review
Raza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K. A., Shifana, A. S., Disouza, J., Saoji, S. D., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145145 · Cited by 14
Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
Sun, Y., Jiang, L., Wen, T., Guo, X., Shao, X., Qu, H., Chen, X., Song, Y., Wang, F., Qu, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670900 · Cited by 13
Regorafenib with or without a programmed cell death protein 1 antibody as third‐line treatment for microsatellite stable metastatic colorectal cancer
He, W., Wang, L., Yin, C., Yi, J., Jin, Y., Jiang, C., Guo, G., & Xia, L. (2022) · Cancer Medicine · doi:10.1002/cam4.5417 · Cited by 13
EBV and MSI Status in Gastric Cancer: Does It Matter?
do Nascimento, C. N., Mascarenhas‐Lemos, L., Silva, J. R., Marques, D. S., Gouveia, C. F., Faria, A., Velho, S., Garrido, R., Maio, R., Costa, A., et al. (2022) · Cancers · doi:10.3390/cancers15010074 · Cited by 14
The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal Cancer
Lisanti, C., Basile, D., Garattini, S. K., Parnofiello, A., Corvaja, C., Cortiula, F., Bertoli, E., Ongaro, E., Foltran, L., Casagrande, M., et al. (2022) · Cancers · doi:10.3390/cancers15010175 · Cited by 16
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
Heinrich, K., Karthaus, M., Fruehauf, S., Graeven, U., Mueller, L., König, A. O., von Weikersthal, L. F., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101568 · Cited by 14
Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis
Wang, P., Chen, Y., Lei, M., He, H., Zhang, D., Lin, J.-P., Lin, H., Wei, W., Chen, P., Zhuang, F.-N., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06004-w · Cited by 11
Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer
Cohen, S. F., Cruiziat, D., Naimer, J., Cohen, V., Kasymjanova, G., Spatz, A., & Agulnik, J. S. (2024) · Current Oncology · doi:10.3390/curroncol31110544 · Cited by 11
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50%
Hektoen, H. H., Tsuruda, K. M., Brustugun, O. T., Neumann, K., & Andreassen, B. K. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105073 · Cited by 11
Effectiveness of immunological agents in non‐small cell lung cancer
Rekulapelli, A., Flausino, L. E., Iyer, G., & Balkrishnan, R. (2022) · Cancer Reports · doi:10.1002/cnr2.1739 · Cited by 11
Sex-related DNA methylation is associated with inflammation and gene expression in the lungs of healthy individuals
Patel, D., McElroy, J., Weng, D. Y., Kamel, S., Reisinger, S. A., Freudenheim, J. L., Wewers, M. D., Shields, P. G., & Song, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-65027-y · Cited by 10
Sex-based differences in lung cancer susceptibility and molecular genetics in the 2020s
Mosleh, B. O., Sarova, P., Zehetmayer, S., Oberndorfer, F., Widder, J., Prosch, H., Idzko, M., Aigner, C., Hoda, M. A., & Gompelmann, D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42089 · Cited by 11
Machine learning models for predicting missing gender in cancer data
Altuhaifa, F. A., & Tuhaifa, M. A. (2025) · International Journal of Data Science and Analytics · doi:10.1007/s41060-025-00771-6 · Cited by 10
Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective study
Jin, J., Visina, J., Burns, T. F., Diergaarde, B. B., & Stabile, L. P. (2023) · Scientific Reports · doi:10.1038/s41598-023-43866-5 · Cited by 10
Sex disparities revealed by single-cell and bulk sequencing and their impacts on the efficacy of immunotherapy in esophageal cancer
Yan, H., Huang, J., Li, Y., & Zhao, B. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00598-z · Cited by 11
Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma
Jia, L., Li, Z., Zhang, C., Zhang, C., & Wang, H. (2020) · Aging · doi:10.18632/aging.103684 · Cited by 10
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
Seesaha, P. K., Wang, K., Guo-qun, W., Cui, T.-Y., Zhao, F., Pan, L., Li, X., Shu, Y., & Chen, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s269671 · Cited by 10
Gender Medicine in Clinical Radiology Practice
Giacobbe, G., Granata, V., Trovato, P., Fusco, R., Simonetti, I., Muzio, F. D., Cutolo, C., Palumbo, P., Borgheresi, A., Flammia, F., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020223 · Cited by 9
Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation
Santo, V., Brunetti, L., Pecci, F., Peroni, M., Barnini, G., Paoloni, F., Buti, S., Tiseo, M., Ricciuti, B., Pinato, D. J., et al. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01718-7 · Cited by 10
Sex-Based Heterogeneity in the Clinicopathological Characteristics and Prognosis of Breast Cancer: A Population-Based Analysis
Han, Y., Wang, J., Wang, Z., & Xu, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642450 · Cited by 10
Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer
Caliman, E., Petrella, M. C., Rossi, V., Mazzoni, F., Grosso, A. M., Fancelli, S., Paglialunga, L., Comin, C., Roviello, G., Pillozzi, S., et al. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220831142452 · Cited by 9
Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
Zhang, Z., Huang, J., Xu, Y., & Luo, H. (2023) · MedComm – Future Medicine · doi:10.1002/mef2.56 · Cited by 8
Gender and sex interactions are intrinsic components of cancer phenotypes
Rubin, J. B. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00829-4 · Cited by 8
Gender oncology: recommendations and consensus of the Italian Association of Medical Oncology (AIOM)
Berardi, R., Rossi, F., Papa, R., Appetecchia, M., Baggio, G., Bianchini, M., Mazzei, T., Moretti, A. M., Ortona, E., Pietrantonio, F., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102243 · Cited by 9
Sex-Biased Immune Responses to Antibiotics during Anti-PD-L1 Treatment in Mice with Colon Cancer
Jing, N., Wang, L., Zhuang, H., Ai, C., Jiang, G., & Liu, Z. (2022) · Journal of Immunology Research · doi:10.1155/2022/9202491 · Cited by 8
Sex-Related Effect on Immunotherapy Response: Implications and Opportunities
Colli, L. M., Morton, L. M., & Chanock, S. J. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz096 · Cited by 8
Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer
Gariazzo, E., Colamartini, F., Ubaldi, M., Santo, V., Brunetti, L., Tomarelli, C., Ognissanti, D., Nassar, J., Costabile, S., Romano, L., et al. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s567238 · Cited by 7
Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study
Frost, M. G., Jensen, K. J., Jimenez‐Solem, E., Qvortrup, C., Andersen, J. A. L., & Petersen, T. S. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108485 · Cited by 7
Relationship between Patients’ Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Hu, X., Liu, Y., He, Y., Wang, Z., Zhang, H., Yang, W., & Lu, J. (2022) · Journal of Oncology · doi:10.1155/2022/3601942 · Cited by 7
Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer
Patel, K. H., Alpert, N., Tuminello, S., & Taioli, E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-682 · Cited by 7
Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis
Lai, J., Kuang, X., Fu, Y., & Li, J. (2024) · Immunotherapy · doi:10.2217/imt-2023-0307 · Cited by 8
Sex as a Biological Variable in Early-Phase Oncology Clinical Trials: Enhancing the Path to Personalised Medicine
Sutherland, L., & Carter, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32597 · Cited by 8
Effect of Gender on Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Real-World Study
Calleja-Chuclá, T., González, P. C., Pradeda, A. M., Pértega-Díaz, S., Margusino‐Framiñán, L., & Antolín, S. (2025) · Biomedicines · doi:10.3390/biomedicines13020437 · Cited by 6
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Braden, J., Potter, A. J., Rawson, R. V., Adegoke, N. A., Lo, S., Conway, J. W., Menzies, A. M., Carlino, M. S., Au‐Yeung, G., Saw, R. P. M., et al. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100776 · Cited by 6
Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?
Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1736 · Cited by 6
Gene regulatory Networks Reveal Sex Difference in Lung AdenocarcinomaPreprint
Saha, E., Guebila, M. B., Fanfani, V., Fischer, J., Shutta, K. H., Mandros, P., DeMeo, D. L., Quackenbush, J. F., & Lopes‐Ramos, C. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.22.559001 · Cited by 6
Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
Decroisette, C., Greillier, L., Curcio, H., Pérol, M., Ricordel, C., Auliac, J. B., Falchero, L., Veillon, R., Vieillot, S., Guisier, F., et al. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000490 · Cited by 5
Sex-specific survival in advanced metastatic melanoma – a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Leven, A., Peters, T., Rajcsanyi, L. S., Weichenthal, M., Mohr, P., Meier, F. E., von Wasielewski, I., Gutzmer, R., Utikal, J., Terheyden, P. A. M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115668 · Cited by 5
Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches
Chang, C., & Chang, Y. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114324 · Cited by 5
Sex‐based immune microenvironmental feature heterogeneity in response to PD ‐1 blockade in combination with chemotherapy for patients with untreated advanced non‐small‐cell lung cancer
Yu, X., You, Z., Liu, Y., Fang, J., Zhao, Q., Sun, Z., Song, Y., Liu, J., & Sun, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7423 · Cited by 5
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Miceli, R., Eriksson, H., Russo, G. L., Alfieri, S., Bjaanæs, M. M., Pietrantonio, F., Cecco, L. D., Prelaj, A., Proto, C., Franzén, J., et al. (2024) · Acta Oncologica · doi:10.2340/1651-226x.2024.24179 · Cited by 5
Immunotherapy in the neoadjuvant settings: a new challenge for the thoracic surgeon?
Bertolaccini, L., Casiraghi, M., & Spaggiari, L. (2019) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivz272 · Cited by 5
Sex-specific T cell exhaustion drives differential immune responses in glioblastomaPreprint
Lee, J., Nicosia, M., Silver, D. J., Li, C., Bayık, D., Watson, D. C., Lauko, A. J., Johnson, S. M., McGraw, M., Grabowski, M. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.17.503211 · Cited by 5
Sex-specific cytokine signatures as predictors of anti-PD1 therapy response in non-small cell lung cancer
Taylor, C., Cheema, A. S., Asleh, K., Finn, N., Abdelsalam, M. G. A., & Ouellette, R. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1583421 · Cited by 5
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
Florez, N., Patel, S. P., Wakelee, H. A., Rotow, J. K., Shum, E., Sands, J. M., Salgia, R., Hirsch, F. R., Peters, S., Sabari, J. K., et al. (2025) · Cancer · doi:10.1002/cncr.70060 · Cited by 4
Multi-omics protein signaling networks identify sex-specific therapeutic candidates in lung adenocarcinoma
Chen, C., Saha, E., Fischer, J., Guebila, M. B., Fanfani, V., Shutta, K. H., Padi, M., Glass, K., DeMeo, D. L., Lopes‐Ramos, C. M., et al. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00752-1 · Cited by 7
Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival
Masetti, M., Petrelli, F., Pietrantonio, F., Lorenzen, S., & Leone, A. G. (2025) · International Journal of Cancer · doi:10.1002/ijc.70312 · Cited by 4
Lung cancer in women: current evidence and future research priorities
Seyyedsalehi, M. S., Cani, M., Wang, Q., Thakur, C., Malapelle, U., Kong, C. Y., Novello, S., & Boffetta, P. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2025.108905 · Cited by 4
The predictive value of 18F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy
Yin, X., Li, J., Chen, B., Liu, K., & Hu, S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107389 · Cited by 4
High Pretreatment DHEA Is Associated with Inferior Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer
Zhang, Y., Darville, L. N. F., Hogue, S., Johnson, J. E. H., Rose, T. A., Kim, Y., Bailey, A., Gray, J. E., & Robinson, L. A. (2024) · Cancers · doi:10.3390/cancers16061152 · Cited by 6
Sex-Based Differences in Lung Cancer: Does It Matter?
Poleri, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.002 · Cited by 4
Sex and gender influence on adverse events for melanoma patients: a comprehensive review and meta-analysis
Gaeta, A., Nuvoli, L., Doccioli, C., Caini, S., Saponara, M., Cimminiello, C., Cosma, C., Palmieri, G., Cossu, A., Vicini, F., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03266-0 · Cited by 3
Disparities in Non-Small Cell Lung Cancer (NSCLC) by Age, Sex, and Race: A Systematic Review and Meta-Analysis of Immune Checkpoint Inhibitor (ICI) Trials
Yaskolko, M., Liu, C., Barsouk, A., Sussman, J., & Barsouk, A. A. (2025) · Cancers · doi:10.3390/cancers18010128 · Cited by 3
Gendermedizin bei Lungenerkrankungen
Klotz, L. V., Deissner, H., & Eichhorn, F. (2024) · Die Chirurgie · doi:10.1007/s00104-024-02141-7 · Cited by 3
The association of azole antifungals with overall survival in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
Sebastian, N., Stokes, W. A., Behera, M., Jiang, R., Gutman, D. A., Huang, Z., Burns, A., Sukhatme, V. V., Lowe, M., Ramalingam, S. S., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae262 · Cited by 3
Let's talk about sex: Survival among females and males in a real‐world cohort treated with pembrolizumab for non‐small cell lung cancer
Tsuruda, K. M., Hektoen, H. H., Aamelfot, C., & Kulle, B. (2025) · International Journal of Cancer · doi:10.1002/ijc.35445 · Cited by 3
Sex and Gender Should Be Considered Continuous Variables in Cancer Research
Yang, W., Wong, J., & Rubin, J. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-91371-6_10 · Cited by 3
Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns
Chakramurty, A., Dinni, A. R., Silvia, I., Cantika, A. L., & Wungu, C. D. K. (2025) · ADMET & DMPK · doi:10.5599/admet.2956 · Cited by 3
Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review
Frega, S., Ferro, A., Bonanno, L., Guarneri, V., Conte, P., & Pasello, G. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-7 · Cited by 2
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
Viñolas, N., Mezquita, L., Corral, J., Cobo, M., Gil, F., Paz-Ares, L. G., Remón, J., Rodríguez, M. F., Ruano‐Raviña, A., Conde, E., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03262-x · Cited by 3
Independent association of sex, age and the melanoma subtype with histological regression in invasive melanomas: A retrospective study
Dessinioti, C., Befon, A., Plaka, M., Polydorou, D., Kypreou, K. P., Champsas, G., & Stratigos, A. (2024) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2024.100020 · Cited by 3
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Guo, Z., Wei, X., Tang, C., & Liang, J. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01298-z · Cited by 3
Precision Immuno-Oncology in NSCLC through Gender Equity Lenses
Marks, J. A., Sridhar, A., Ai, A., Kiel, L., Kaufman, R. A., Abioye, O. F., Mantz, C., & Florez, N. (2024) · Cancers · doi:10.3390/cancers16071413 · Cited by 3
Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer
Wang, S., Zhang, Y., Chen, G., Zhao, P., Wang, X., Xu, B., & Yuan, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111988 · Cited by 3
Sex differences in prognosis factors in patients with lung cancer: A nationwide retrospective cohort study in Korea
Huh, Y., Sohn, Y. J., Kim, H.-R., Chun, H., Kim, H. J., & Son, K. Y. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300389 · Cited by 3
Sex Matters–Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer
Schulz, B., Leitner, E., Schreiber, T., Lindner, T., Schwarz, R., Aboutara, N., Ma, Y., Escobar, H. M., Palme, R., Hinz, B., et al. (2024) · Cancers · doi:10.3390/cancers16101901 · Cited by 3
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study
Zhao, D. B., Bi, M., Cheng, X., Wang, S., Cheng, H., Xia, X., Chen, H., Zhang, Y., Hu, Z., Cao, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1494708 · Cited by 3
Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender
Stukan, А. I., Murashko, R. A., Tsygan, N. A., Goryainova, А. Y., Nefedov, O. N., & Porkhanov, V. A. (2022) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2022-12-3-114-126 · Cited by 3
NSCLC in Vulnerable and Special Populations: Toward Personalized Care
Parisi, C., Giglio, A. D., Banini, M., Tagliamento, M., Rousseau, A., Frélaut, M., Fusco, F., Mantuano, F., Favorito, V., Cappuzzo, F., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103705 · Cited by 2
Effect of Smoking Status on the Efficacy of EGFR-TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
Qin, B., Jiao, X., Wang, Y., Wu, Y. X., Ling, Y., Liu, K., & Zang, Y. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.06.006 · Cited by 2
CIA‐II is associated with lower‐grade glioma survival and cell proliferation
Xiao, F., Zhu, H., Guo, Y., Zhang, Z., Sun, G., Xiao, Y., Hu, G., Huang, K., & Guo, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14340 · Cited by 2
Metastatic pattern and prognosis in patients with lung adenosquamous carcinoma: A surveillance, epidemiology, and end results-based population study
Xie, J., & Li, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30641 · Cited by 2
Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review
Kang, W., Cheng, J., Pan, L., Zhan, P., Liu, H., Lv, T., Han, H., & Song, Y. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1334957 · Cited by 2
An Anthropometric Study of Total Body Nevus Counts, Height, Sex, and Age Differences
Dessinioti, C., Tsiakou, A., & Stratigos, A. J. (2025) · International Journal of Dermatology · doi:10.1111/ijd.17937 · Cited by 2
Accounting for sex differences as a continuous variable in cancer treatmentsPreprint
Rubin, J. B., & Yang, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3120372/v1 · Cited by 2
Identifying Sex Differences in Lung Adenocarcinoma Using Multi-Omics Integrative Protein Signaling NetworksPreprint
Chen, C., Saha, E., Fischer, J., Guebila, M. B., Fanfani, V., Shutta, K. H., Padi, M., Glass, K., DeMeo, D. L., Lopes‐Ramos, C. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.03.636354 · Cited by 2
Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective
Vavalà, T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.09.004 · Cited by 1
Development and validation of a prognostic model for patients with cT1-4N1-3M1 esophageal squamous cell carcinoma: based on the SEER database and the Chinese cohort study
Wang, X., Liu, C.-T., Huang, J.-T., Zhang, Z.-H., Xu, Y., Wu, F., & Peng, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1547462 · Cited by 1
What can we learn from an intersectionality-informed description of study participants? Results from the German National Cohort
Jaehn, P., Rach, S., Bolte, G., Mikolajczyk, R., Merz, S., Herrera-Espejel, P. S., Brand, T., Führer, A., Berger, K., Teismann, H., et al. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-025-02521-3 · Cited by 1
50-Year age threshold for early-onset NSCLC: A SEER-TCGA retrospective analysis reveals a prognostic paradox based on age treatment response
Lu, Z., Zheng, P., Liao, Y., Wang, H., Zhu, K., Chen, Y., Lin, Z., Huang, X., Wang, Y., & Yang, J. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003770 · Cited by 1
Pre-treatment endocrine–nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies
Huang, N., & Guan, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1753660 · Cited by 1
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
Parisi, C., Banini, M., Mantuano, F., Aldea, M. D., Abdayem, P., Derosa, L., Frélaut, M., Lavaud, P., Robert, A., Simon, S., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107773 · Cited by 1

Authors: Conforti, F., Pala, L., Bagnardi, V., Viale, G., De Pas, T., Pagan, E., Pennacchioli, E., Cocorocchio, E., Ferrucci, P. F., De Marinis, F., Gelber, R. D., & Goldhirsch, A.
Affiliations: See the Notes section for the full list of authors’ affiliations
Corresponding author: Conforti, Fabio
ORCID: Conforti, Fabio
Pala, Laura
Bagnardi, Vincenzo
Viale, Giuseppe
Pagan, Eleonora
Pennacchioli, Elisabetta
Cocorocchio, Emilia
Ferrucci, Pier Francesco
Gelber, Richard D
Venue: JNCI: Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2019-05-20
Volume: 111
Issue: 8
Pages: 772-781
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/djz094
PMC: PMC6695312
OpenAlex: W2946644285
Cited by: 262
References: 34
Citations by year: 2026: 23 · 2025: 39 · 2024: 56 · 2023: 36 · 2022: 36 · 2021: 39 · 2020: 28 · 2019: 4
FWCI: 2.55
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
PubMed Central (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: sex differences, lung cancer immunotherapy, immune checkpoint inhibitors, anti-PD-1, PD-L1 inhibitors, anti-CTLA-4, non-small cell lung cancer, combination chemotherapy, overall survival, first-line systemic treatment
MeSH terms: Female, Humans, Immunotherapy, Lung Neoplasms, Male, Sex Characteristics, Disease-Free Survival, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks